UroGen Pharma (LTS:0XOD) Dividend Payout Ratio: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0XOD UroGen Pharma Ltd LTS:0XOD
53 GF Score
Price $43.44
GF Value $29.57
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is UroGen Pharma Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. UroGen Pharma's Dividend Payout Ratio for the months ended in Jun. 2026 was .

The historical rank and industry rank for UroGen Pharma's Dividend Payout Ratio or its related term are showing as below:


LTS:0XOD's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.4
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-09-19), the Dividend Yield % of UroGen Pharma is 0.00%.

UroGen Pharma's Dividends per Share for the months ended in Jun. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

UroGen Pharma (LTS:0XOD) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

UroGen Pharma Dividend Payout Ratio Related Terms

UroGen Pharma Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Dividend Payout Ratio Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only

UroGen Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only

LTS:0XOD vs PVLA, KLRA, VCEL: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, UroGen Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Dividend Payout Ratio falls into.


LTS:0XOD
53GF Score
UroGen Pharma Ltd LTS:0XOD
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

UroGen Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ -3.19
=N/A

UroGen Pharma's Dividend Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2026 )/ EPS without NRI (Q: Jun. 2026 )
=0/ -0.285
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of $43.44 is trading 46.9% above its estimated GF Value™ of $29.57. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0XOD:

  • Dividend Payout Ratio:
  • GF Value™: $29.57 vs. price of $43.44 (46.9% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USAUR8:Germany
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
53GF Score

Get the complete analysis for LTS:0XOD

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.44
Price
$29.57
GF Value